July 24, 2013
Clinical Trial Results Show Two New Gonorrhea Treatment Combinations
A recent CDC and National Institutes of Health clinical trial aimed at identifying new gonorrhea treatment options in the face of growing antibiotic resistance proved successful . The trial investigated the efficacy of injectable gentamicin in combination with oral azithromycin, and oral gemifloxacin in combination with oral azithromycin. All of these medications are approved by the U.S. Food and Drug Administration and are available in the United States; however, this is the first clinical trial to evaluate them as combination therapy for gonorrhea.
This clinical trial addresses a DSTDP focus area: antibiotic-resistant gonorrhea. Data show increasing resistance to the antibiotic drugs recommended to treat gonorrhea, so development of new treatment options is crucial. The results of this clinical trial do not change current gonorrhea treatment guidelines. CDC will take the findings of this trial into consideration for inclusion in future treatment guidelines. The study’s principal investigator, DSTDP’s Dr. Robert Kirkcaldy, presented the findings at the meeting of The International Society for Sexually Transmitted Diseases Research in mid-July.
CDC Launches STD Treatment Guidelines App
DSTDP recently launched a free STD Treatment Guidelines mobile app for health care providers called STD Tx Guide. Providers who use this app will have quick access to current information about the diagnosis and treatment of 21 STDs and the useful booklet A Guide to Taking a Sexual History. The app is available for Apple and Android devices.
New HPV Study Shows Vaccine Lowering HPV Rates in Teen Girls
A new study led by DSTDP’s Dr. Lauri Markowitz and colleagues examined the prevalence of HPV infections in girls and women before and after the introduction of the HPV vaccine. The study, published in the June issue of The Journal of Infectious Diseases, revealed that since the HPV vaccine was introduced in 2006, vaccine-type HPV prevalence has decreased 56 percent among female teenagers 14-19 years of age—a significant reduction. “The decline in vaccine type prevalence is higher than expected and could be due to factors such as herd immunity, high effectiveness with less than a complete three-dose series and/or changes in sexual behavior we could not measure,” said Dr. Markowitz. The promising study results have public health experts and clinicians looking forward to improving HPV vaccine uptake. Additional information on this study can be found in a media release issued by CDC. The conversation about HPV prevention will continue with a Twitter chat hosted by CDC Director Dr. Tom Frieden on Monday, July 29 at 3 PM ET. STD, vaccine, and cancer experts from across the agency will also participate in this Twitter Chat. To join, follow Dr. Frieden on Twitter @DrFriedenCDC and use the hashtag #CDCchat.
Mark Your Calendars: Call for Abstracts – 2014 STD Prevention Conference
The 2014 STD Prevention Conference Scientific Program Committee will begin accepting abstracts for the oral and poster presentations in the areas of STD prevention research, program, and policy on September 2, 2013. Abstracts will be accepted until October 25, 2013.
The Scientific Program for the 2014 STD Prevention Conference is structured to reflect a program science framework -- the new direction of STD prevention in the United States and globally. Please visit the 2014 STD Prevention Conference Call for Abstracts page for additional details about submission requirements, information about late breaker abstracts, and satellite meetings.
New STDP AAPPS Funding Opportunity Announcement Replaces CSPS
Last month, DSTDP published a new funding opportunity announcement (FOA) titled Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies (STD AAPPS). STD AAPPS will replace the current Comprehensive STD Prevention Systems (CSPS) cooperative agreement which expires at the end of this year. The full text of the FOA, frequently asked questions, and other resources can be found on the STD AAPPS FOA website. If you have questions, please direct them to STDAAPPSFOA@cdc.gov.
Get Ready for the New Health Insurance Marketplace
Beginning October 1, millions of Americans will have a new way to find affordable health coverage--including many free preventive services-- on the new Health Insurance Marketplace. The Marketplace will offer Americans a whole new way to shop for health insurance to gain greater access to affordable services such as physician visits, preventive care, hospital stays, and prescriptions. Through the same streamlined application process, many will find out if they are eligible for Medicaid or the Children’s Health Insurance Program (CHIP) at the Marketplace. Community health centers and other organizations will be funded to help consumers navigate the new Marketplace. Consumers can learn more about the Marketplace now and get ready to enroll by visiting HealthCare.gov or the Spanish-language site CuidadoDeSalud.gov or by calling the new 24-hours-a-day consumer call center at 1-800-318-2596. Hearing impaired callers using TTY/TDD technology can call 1-855-889-4325 for assistance.
Upcoming Events for DSTDP
Twitter Chat: Preventing HPV
July 29, 2013 3:00-4:00 pm, ET
Program evaluation, quality improvement, and performance management: Understanding how they relate and their role in public health programs Webinar
August 6, 2013 3:00-4:00 pm, ET